DFFN: Diffusion Pharmaceuticals Inc. - Summary | Jitta

Diffusion Pharmaceuticals Inc.

NASDAQ:DFFN

Notice
Stock data is unavailable or the company’s delisted.
Price
$6.60
Loss Chance
58.4%
0.21JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (7)
Recent Business Performance (22)
Financial Strength (30)
Return to Shareholders (0)
Competitive Advantage (6)
Jitta Signs
SG&A to SalesDecreasing Every Year
Cash Conversion CycleLess than 30 days
Recent Business PerformanceEarning decline 7.76% in the last year
New Share IssuedMore than 50% in 5 years
CapExVery High
SG&A to SalesIncreasing Every Year
Key Stats
Jitta Score
Jitta Line
0.21
100.00%
1.92
350.25%
1.92
350.25%
4.41
53.66%
3.32
38.04%
2.67
16.43%
COMPANY DESCRIPTION
As of August 16, 2023, CervoMed Inc. was acquired by EIP Pharma, Inc., in a reverse merger transaction. Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body’s ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.